Inhibition of FAK-Actin Pathway by Indoxyl Sulfate Suppresses Microvascular Remodeling in a Mouse Model of Chronic Kidney Disease
- 1Center for Molecular and Translational Medicine, Georgia State University, Atlanta, GA 30303, USA
- 2Department of Endocrinology and Metabolism, Tianjin Medical University General Hospital, Tianjin 300052, China
Abstract
Objective: Chronic kidney disease (CKD) worsens outcomes of peripheral artery diseases (PADs), partly through impaired vascular regeneration and microvascular remodeling. CKD promotes the accumulation of uremic toxins, but their contributions to microvascular dysfunction remain poorly understood. This study investigated the effects of uremic toxin indoxyl sulfate (IS) on vascular smooth muscle cell (VSMC) function and microvascular remodeling in a mouse model of CKD. Methods: C57BL6/J mice were fed 0.25% adenine diet for 10 days to induce CKD. CKD mice underwent hindlimb ligation surgery. VSMC migration assays, microscopy, and Western blotting were utilized to elucidate the underlying mechanisms underlying the IS-induced impairment of vascular remodeling. Results: CKD mice exhibited significantly impaired blood flow restoration (44.7% relative blood flow) compared with controls (82.6% relative blood flow) accompanied by a reduced α-smooth muscle expression and decreased formation of smooth muscle-covered micro vessels in ischemic limbs. Wound healing and transwell migrations assays demonstrated IS significantly reduced VSMC motility. IS-exposure also disrupted actin cytoskeletal organization, impaired cell attachment, reduced cell size, and decreased focal adhesion formation. Mechanistically, IS reduced focal adhesion kinase (FAK) expression, impairing VSMC adhesion and migration. Reduced FAK signaling was associated with decreased N-WASP expression and suppression of the Arp2/3 complex, which regulates actin polymerization and cytoskeletal remodeling. These alterations suggest that IS disrupts the cellular processes required for VSMC recruitment and structural remodeling of the microvascular, potentially limiting vessel maturation and stabilization during ischemic recovery. Conclusions: IS impairs VSMC migration and cytoskeletal organization through the disruption of the FAK-N-WASP-Arp2/3 signaling axis, contributing to defective microvascular remodeling and impaired perfusion recovery in CKD-associated PAD. These findings identify uremic toxin-mediated cytoskeletal dysfunction as a potential therapeutic target for improving microvascular regeneration and vascular recovery in patients with CKD.
Related
- Inhibition of Bone Morphogenetic Protein 2 Suppresses the Stemness Maintenance of Cancer Stem Cells in Hepatocellular Carcinoma via the MAPK/ERK Pathway [Retraction].
- PARG inhibition suppresses osteoclast differentiation through transcriptional activation of an NRF2-dependent pathway
- Medicarpin suppresses gastric cancer growth in association with inhibition of mevalonate pathway-associated cholesterol biosynthesis
- Apigenin suppresses ovarian cancer cell growth by disrupting TGF-beta1-mediated cancer–stroma interaction via AKT inhibition
- Gilteritinib Suppresses Hepatocellular Carcinoma Cells in Association with Reduced Calpain-1 Expression and Inhibition of STAT3/AKT Signaling
BibTeX
@article{carr2026inhibition,
title = {{Inhibition of FAK-Actin Pathway by Indoxyl Sulfate Suppresses Microvascular Remodeling in a Mouse Model of Chronic Kidney Disease}},
author = {Sean Michael Carr and Tharmarajan Ramprasath and Ming-Hui Zou},
journal = {Cells},
year = {2026},
month = oct,
doi = {10.3390/cells15211946},
url = {https://www.mdpi.com/2073-4409/15/21/1946},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Inhibition of FAK-Actin Pathway by Indoxyl Sulfate Suppresses Microvascular Remodeling in a Mouse Model of Chronic Kidney Disease
AU - Sean Michael Carr
AU - Tharmarajan Ramprasath
AU - Ming-Hui Zou
PY - 2026
DA - 2026/10/26
JO - Cells
DO - 10.3390/cells15211946
UR - https://www.mdpi.com/2073-4409/15/21/1946
AB - Objective: Chronic kidney disease (CKD) worsens outcomes of peripheral artery diseases (PADs), partly through impaired vascular regeneration and microvascular remodeling. CKD promotes the accumulation of uremic toxins, but their contributions to microvascular dysfunction remain poorly understood. This study investigated the effects of uremic toxin indoxyl sulfate (IS) on vascular smooth muscle cell (VSMC) function and microvascular remodeling in a mouse model of CKD. Methods: C57BL6/J mice were fed 0.25% adenine diet for 10 days to induce CKD. CKD mice underwent hindlimb ligation surgery. VSMC migration assays, microscopy, and Western blotting were utilized to elucidate the underlying mechanisms underlying the IS-induced impairment of vascular remodeling. Results: CKD mice exhibited significantly impaired blood flow restoration (44.7% relative blood flow) compared with controls (82.6% relative blood flow) accompanied by a reduced α-smooth muscle expression and decreased formation of smooth muscle-covered micro vessels in ischemic limbs. Wound healing and transwell migrations assays demonstrated IS significantly reduced VSMC motility. IS-exposure also disrupted actin cytoskeletal organization, impaired cell attachment, reduced cell size, and decreased focal adhesion formation. Mechanistically, IS reduced focal adhesion kinase (FAK) expression, impairing VSMC adhesion and migration. Reduced FAK signaling was associated with decreased N-WASP expression and suppression of the Arp2/3 complex, which regulates actin polymerization and cytoskeletal remodeling. These alterations suggest that IS disrupts the cellular processes required for VSMC recruitment and structural remodeling of the microvascular, potentially limiting vessel maturation and stabilization during ischemic recovery. Conclusions: IS impairs VSMC migration and cytoskeletal organization through the disruption of the FAK-N-WASP-Arp2/3 signaling axis, contributing to defective microvascular remodeling and impaired perfusion recovery in CKD-associated PAD. These findings identify uremic toxin-mediated cytoskeletal dysfunction as a potential therapeutic target for improving microvascular regeneration and vascular recovery in patients with CKD.
SN - 2073-4409
ER -